HarmonKGAsifIMMaleszewskiJJ, et al.Incidence, etiology, and comparative frequency of sudden cardiac death in NCAA athletes: A decade in review. Circulation2015; 132: 10–19.
3.
MontLPellicciaASharmaS, et al.Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Eur J Prev Cardiol2017; 24: 41–69.
4.
CaselliSVaquer SequiALemmeE, et al.Prevalence and management of systemic hypertension in athletes. Am J Cardiol2017; 119: 1616–1622.
5.
MarchionniNFattirolliFFumagalliS, et al.Improved exercise tolerance and quality of life with cardiac rehabilitation of older patients after myocardial infarction: Results of a randomized, controlled trial. Circulation2003; 107: 2201–2206.
6.
ReevesGRWhellanDJO’ConnorCM, et al.A novel rehabilitation intervention for older patients with acute decompensated heart failure. The REHAB-HF pilot study. J Am Coll Cardiol Heart Fail2017; 5: 359–366.
7.
PiepoliMFHoesAWAgewallS, et al.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol2016; 23: NP1–NP96.
8.
Bjarnason-WehrensBMayer-BergerWMeisterER, et al.Recommendations for resistance exercise in cardiac rehabilitation. Recommendations of the German Federation for Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil2004; 11: 352–361.
9.
RamosRComas-CufíMMartí-LluchR, et al.Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ2018; 362: k3359–k3359.
10.
CarneyRMFreedlandKE. Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry2009; 166: 410–417.
11.
KimJMBaeKYStewartR, et al.Escitalopram treatment for depressive disorder following acute coronary syndrome: A 24-week double-blind, placebo-controlled trial. J Clin Psychiatry2015; 76: 62–68.
